Cover Image
市場調查報告書

組織工程及再生醫療:各種技術和全球市場

Tissue Engineering and Regeneration: Technologies and Global Markets

出版商 BCC Research 商品編碼 228043
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
組織工程及再生醫療:各種技術和全球市場 Tissue Engineering and Regeneration: Technologies and Global Markets
出版日期: 2016年09月30日 內容資訊: 英文 194 Pages
簡介

全球組織工程及再生醫療的市場,預計2016年成長達136億美元的規模,此後預計到2021年以34.9%的年複合成長率發展,2021年達到608億美元的規模。

本報告提供全球組織工程及再生醫療的市場相關調查,各種技術、材料、用途種類與概要,各技術、材料、用途、地區的市場成長預測,影響市場成長因素及市場機會分析,未來展望相關分析,主要產品詳細內容,競爭環境分析,主要企業簡介等,詳細內容彙整。

第1章 簡介

第2章 摘要

第3章 組織工程和組織的再生

  • 組織工程產業的演進和確實性
  • 組織再生的奈米技術
  • 基因治療:組織工程的未來
  • 幹細胞技術:對組織工程來說的恩惠
  • 政府的法律規章
  • 組織工程的生物印刷技術
  • 波特的五力分析
  • 臨床試驗
  • 市場動態

第4章 組織工程、組織再生市場分析:各構成要素

  • 細胞療法
  • 幹細胞療法
  • 幹細胞起源
  • 現有及開發階段的幹細胞產品
  • 組織的血管新生
  • 細胞培養技術
  • 小分子及生技藥品
  • 小分子
  • 生技藥品
  • 免疫療法

第5章 組織工程、組織再生市場分析:各材料

  • 合成材料
  • 恰當的基礎 (scaffold):醫療用聚乳酸
  • 生物來源材料
  • 遺傳基因操作材料
  • 小分子及生技藥品

第6章 組織工程、組織再生市場分析:各用途

  • 循環系統疾病
  • 腫瘤學
  • 皮膚科學
  • 肌肉骨骼用途
  • 創傷治療
  • 眼科學
  • 神經學
  • 神經系統疾病
  • 內臟器官的再生

第7章 組織工程、組織再生市場分析:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 競爭環境

  • 核准
  • 協定,擴大及合作
  • 新產品發表、專利認證
  • M&A

第9章 專利分析

第10章 企業簡介

  • ARTERIOCYTE MEDICAL SYSTEMS INC.
  • ATHERSYS INC.
  • CERAPEDICS INC.
  • CO.DON AG
  • COOK MEDICAL INC.
  • CRYOLIFE INC.
  • CYTORI THERAPEUTICS INC.
  • GENZYME CORP.
  • KINETIC CONCEPTS INC.
  • MESOBLAST LTD.
  • NUO THERAPEUTICS INC. (CYTOMEDIX INC.)
  • OCATA THERAPEUTICS INC. (ASTELLAS PHARMA INC.)
  • ORGANOGENESIS INC. (ADVANCED BIOHEALING)
  • ORTHOPEUTICS L.P.
  • U.S. STEM CELL INC. (BIOHEART INC.)
  • VERICEL CORP. (AASTROM BIOSCIENCES INC.)
  • WRIGHT MEDICAL GROUP N.V

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC101C

The global market for tissue engineering and regeneration is expected to reach $60.8 billion by 2021 from $13.6 billion in 2016, rising at a compound annual growth rate (CAGR) of 34.9% from 2016 through 2021.

This report provides:

  • An overview of the global market for tissue engineering and regeneration, and related technologies.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Information on the specific drivers, trends, and challenges for different segments of the market.
  • Valuable insight into future trends, details on products, and information on therapies available in the field of tissue engineering.
  • Analysis of the competitive environments, including new and potential markets for novel therapies and treatments.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF THE REPORT

This report covers all the revenues earned by the regeneration therapies. These therapies are extensively used to replace and regenerate the cells, genes and tissues in a patient's body. The report considers revenue generated by the products, as well as services in the regenerative medicine market. The services include the tools, along with the cell and gene bank charges, where the cells and tissues are stored and treated properly pre- and post-experimentation and treatment. The report also covers the revenues earned by small molecules and biologics (drugs) that speed up the regeneration process. Other drug therapy revenues (e.g., painkillers, analgesics) that can be used along with regenerative therapy are not included in the report, as they do not contribute to cell or tissue regeneration. The report covers all the existing applications of the regenerative medicine therapy.

The global tissue engineering and regeneration market is primarily segmented by components, materials, applications and region. The tissue engineering and regenerative medicine component market is categorized into therapeutic products, tools, banks and services. These therapeutic products are further segmented into cell therapy, gene therapy, tissue engineering, and small molecules and biologics based on product type.

The therapeutic products are also categorized into synthetic materials, biologically derived materials, genetically engineered materials, and small molecules and biologics based on material. The report includes key technologies involved in regenerative medicine therapy. The study analyzes the clinical trials and patents conducted in respective regions. The report provides an in-depth analysis of the key companies operating in the global tissue engineering and regeneration market.

The market is segmented by region as North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, CeraPedics, Cook Biotech, CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.

ANALYST'S CREDENTIALS

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life science market and the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to assist market players make beneficial strategies. Ms. Jeevane holds a MBA degree in Marketing.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • SCOPE OF THE REPORT
  • INTENDED AUDIENCE
  • SOURCE OF INFORMATION AND METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY REGION, 2015-2021 ($ MILLIONS)

CHAPTER 3 TISSUE ENGINEERING AND REGENERATION MARKET OVERVIEW

  • PROGRESS AND PROMISES FOR TISSUE ENGINEERING INDUSTRY
  • FIGURE 1 TISSUE ENGINEERING STRATEGIES
  • BODY PARTS THAT CAN BE REPLACED BY TISSUE ENGINEERING
  • NANOTECHNOLOGY FOR TISSUE REGENERATION
  • FIGURE 2 NANOTECHNOLOGY AND TISSUE REGENERATION
    • EFFECTS OF NANOTECHNOLOGY ON STEM CELL BEHAVIOR FOR TISSUE REGENERATION
      • Nanoparticles
      • Nanoscaffolds
    • NANOTECHNOLOGY IN TISSUE REGENERATION APPLICATIONS
      • Bone and Cartilage Regeneration
      • Vascular Tissue Regeneration
      • Neural Tissue Regeneration
  • GENE THERAPIES: THE FUTURE OF TISSUE ENGINEERING
    • PROGRESS
    • PROSPECTS
  • STEM CELL TECHNOLOGIES BOON TO TISSUE ENGINEERING
  • GOVERNMENT REGULATIONS AND LEGISLATIONS
    • REGULATIONS FOR TISSUE ENGINEERING PRODUCTS IN EUROPE AND THE U.S.
    • CHINESE REGULATIONS FOR TISSUE ENGINEERING
    • REGULATORY DIFFERENCES
    • TABLE 1 U.S. AND EUROPEAN DIFFERENCES IN REGULATORY APPROVAL
    • ETHICAL ISSUES OF STEM CELL THERAPIES AND CORD BLOOD BANKING
      • Ethical Issues Regarding Cord Blood Banking
      • Ethical Issues in Cord Blood Stem Cell Therapies
    • IMPACT OF HEALTHCARE SYSTEM ON TISSUE ENGINEERING MARKET DEVELOPMENT
    • TABLE 2 MAIN ASPECTS OF HEALTHCARE PROVISIONS IN DIFFERENT COUNTRIES
  • BIOPRINITING TECHNOLOGY IN REGENERATIVE MEDICINE
  • PORTER'S FIVE FORCES ANALYSIS OF TISSUE ENGINEERING AND REGENERATION MARKET
  • FIGURE 3 PORTER'S FIVE FORCES MODEL FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE MARKET
    • MODERATE BARGAINING POWER OF SUPPLIER
    • LOW BARGAINING POWER OF BUYER
    • MODERATE TO LOW-LEVEL OF THREATS FROM SUBSTITUTE PRODUCTS
    • CLINICAL TRIALS
    • U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING
    • TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING, BY COMPANY, 2010-2016
    • TABLE 4 COMPLETED U.S. CLINICAL TRIALS CONDUCTED FOR TISSUE ENGINEERING, 2004-2015
      • Terminated Clinical Trials for Tissue Engineering
      • TABLE 5 TERMINATED U.S. CLINICAL TRIALS, 2012-2018
    • EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING
    • TABLE 6 EUROPEAN CLINICAL TRIALS CONDUCTED FOR TISSUE ENGINEERING, 2009-2019
  • MARKET DYNAMICS
    • DRIVERS
      • Emergence of Stem Cell Technology
      • FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2011-2016 (NO. OF STUDIES)
      • Prominent Potential of Nanotechnology
      • Rise in Prevalence of Trauma Emergencies and Chronic Diseases
      • Advancement in Surgical Technologies and Monitoring Devices
    • RESTRAINTS
      • Operational Inefficiency
      • Stringent Regulatory Policies and Ethical Issues
      • High Cost of Treatments
    • OPPORTUNITIES IN STEM CELL APPLICATIONS
      • Core Competency in Emerging Economies
      • Increasing Gap in Donors to Patients for Organ Transplantation

CHAPTER 4 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY COMPONENTS

  • TABLE 7 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 8 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY THERAPEUTIC PRODUCT, THROUGH 2021 ($ MILLIONS)
  • CELL THERAPY
    • AUTOLOGOUS CELL THERAPIES
    • ALLOGENIC CELL THERAPIES
    • XENOGENEIC CELL THERAPIES
    • TABLE 9 GLOBAL CELL THERAPY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • STEM CELL THERAPY
  • STEM CELL SOURCES
  • EXISTING AND DEVELOPMENT-STAGE STEM CELL PRODUCTS
    • CLINICAL APPLICATION OF STEM CELL TECHNOLOGIES IN THE COMMERCIAL MARKET
      • Cardiovascular Repair
      • Neural Repair
      • Bone Repair
      • Skeletal Muscle Repair
      • Urologic Repair
  • TISSUE VASCULARIZATION
  • CELL CULTURING
  • TABLE 10 PROJECTS AND THEIR ASSESSMENT STAGES (£)
  • SMALL MOLECULES AND BIOLOGICS
  • TABLE 11 GLOBAL SMALL MOLECULES AND BIOLOGICS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SMALL MOLECULES
  • BIOLOGICS
  • TISSUE ENGINEERING
  • TABLE 12 GLOBAL TISSUE ENGINEERING MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • GENE THERAPY
  • TABLE 13 GLOBAL GENE THERAPY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • CELL ELIMINATION
    • GENE ADDITION
    • GENE CORRECTION
    • GENE SILENCING
    • REPROGRAMMING

CHAPTER 5 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY MATERIAL

  • TABLE 14 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY THERAPEUTIC MATERIAL, THROUGH 2021 ($ MILLIONS)
  • SYNTHETIC MATERIALS
  • TABLE 15 GLOBAL SYNTHETIC MATERIAL MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 16 GLOBAL SYNTHETIC MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • BIODEGRADABLE SYNTHETIC POLYMERS
    • TABLE 17 BIODEGRADABLE POLYMER CLASSIFICATION
    • TABLE 18 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SCAFFOLDS: MEDICAL POLY LACTIC ACID
  • TABLE 19 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS
  • TABLE 20 GLOBAL SCAFFOLD MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • ARTIFICIAL VASCULAR GRAFT MATERIALS
      • Integration of Stem Cell in Vascular Tissue Engineering
        • ECM-Based Vascular Grafts
        • Cell Sheets Without Scaffold Support
        • TABLE 21 GLOBAL ARTIFICIAL VASCULAR GRAFT MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • HYDROGEL TECHNOLOGY
    • TABLE 22 GLOBAL HYDROGEL TECHNOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • BIOLOGICALLY DERIVED MATERIALS
  • TABLE 23 GLOBAL BIOLOGICALLY DERIVED MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 GLOBAL BIOLOGICALLY DERIVED MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • COLLAGEN
    • TABLE 25 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • Animal-Derived
      • Recombinant
    • XENOGENIC TISSUE
    • TABLE 26 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • Polypeptides
      • Fibrins
      • Glycosaminoglycans
  • GENETICALLY ENGINEERED MATERIALS
  • TABLE 27 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS
    • TABLE 29 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • GENETICALLY MANIPULATED CELLS
    • TABLE 30 GLOBAL GENETICALLY MANIPULATED CELL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • THREE-DIMENSIONAL POLYMER TECHNOLOGY
    • TABLE 31 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TRANGENICS
    • TABLE 32 GLOBAL TRANSGENIC MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIBROBLASTS
    • TABLE 33 GLOBAL FIBROBLAST MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • NEURAL STEM CELLS
    • TABLE 34 GLOBAL NEURAL STEM CELL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • GENE-ACTIVATED MATRICES
    • TABLE 35 GLOBAL GENE-ACTIVATED MATRIX MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SMALL MOLECULES AND BIOLOGICS
  • TABLE 36 GLOBAL MARKET FOR SMALL MOLECULES AND BIOLOGICS, BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 6 TISSUE ENGINEERING AND REGENERATION MARKET BY APPLICATION

  • TABLE 37 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET, BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR CARDIOVASCULAR DISORDERS
  • TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • PERIPHERAL VASCULAR DISEASE APPLICATIONS
    • CORONARY ARTERY DISEASE APPLICATIONS
      • Heart Valves and Tissue Engineering
      • Mechanical Heart Valves
      • Biological Heart Valves
      • TABLE 39 CELL THERAPIES BY DIFFERENT COMPANIES TO TREAT CADIOVASULAR DISEASES
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR ONCOLOGY
  • FIGURE 5 T-CELL THERAPY TECHNIQUE
  • TABLE 40 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR ONCOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR DERMATOLOGY
  • TABLE 41 GLOBAL AND U.S. STATISTICS FOR SKIN DAMAGE MEDICAL CONDITIONS, 2011
  • TABLE 42 ACELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 43 CELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 44 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR
  • DERMATOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR MUSCULOSKELETAL APPLICATIONS
    • ORTHOPEDIC APPLICATIONS
    • TABLE 45 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR MUSCULOSKELETAL APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 46 ORTHOPEDIC DISEASES BY REGION: KEY FACTS
    • BONE REPAIR AND REPLACEMENT
    • TABLE 47 BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011 (NO. OF PEOPLE)
    • TREATMENT FOR CARTILAGE AND CONNECTIVE TISSUE DAMAGE
    • CURRENT TISSUE-ENGINEERED PRODUCTS FOR BONE DEFECTS
    • CARTILAGE REPAIR AND REPLACEMENT
    • TABLE 48 GLOBAL STATISTICS FOR CARTILAGE DAMAGE, 2007
    • MENISCUS REPAIR AND REPLACEMENT
    • TENDON AND LIGAMENT REPAIR AND REPLACEMENT
    • MUSCLE REGENERATION
    • TABLE 49 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING
    • PERIPHERAL NERVE REPAIR
    • HERNIA AND SOFT TISSUE REPAIR
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR WOUND HEALING
  • TABLE 50 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR WOUND HEALING APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • BURN TREATMENT
    • ULCER TREATMENT
    • ANTI-AGING THERAPIES
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR OPHTHALMOLOGY
  • TABLE 51 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR
  • OPHTHALMOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE FOR NEUROLOGY
    • CENTRAL NERVOUS SYSTEM
    • TABLE 52 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR NEUROLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM DISEASES
    • NEUROSURGICAL
      • Cell Implants for Parkinson's Diseases
      • TABLE 53 GLOBAL STATISTICS FOR NEURODEGENERATIVE DISEASES, 2015
      • Cell Transplants for Epilepsy Treatment
      • Stem Cell Therapy for Multiple Sclerosis
    • SPINAL CORD INJURY: SPINAL DISC REPAIR AND REPLACEMENT
    • TABLE 54 U.S. STATISTICS FOR SPINAL CORD INJURIES, 2015
      • Spinal Cord Injury Treatments
        • Tissue Engineering for Spinal Cord Injury
        • Cell Therapy for Spinal Cord Injuries
        • Scaffold Approach for Spinal Cord Injury Treatment
    • OTHERS
      • Dental Tissue Engineering
      • TABLE 55 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • INTERNAL ORGAN REGENERATION
    • LIVER REGENERATION
    • TABLE 56 U.S. STATISTICS FOR LIVER FAILURE, 2011
    • TABLE 57 ARTIFICIAL LIVER SUPPORT SYSTEMS
    • PANCREAS AND ISLET CELL REGENERATION
    • TABLE 58 U.S. STATISTICS FOR PANCREATIC CANCER AND DIABETES, 2010
    • KIDNEY AND RENAL TUBULE REGENERATION
    • TABLE 59 U.S. STATISTICS FOR KIDNEY DISEASES, 2013

CHAPTER 7 TISSUE ENGINEERING AND REGENERATION MARKET BY REGION

  • FIGURE 6 REGENERATIVE MEDICINE COMPANIES BY SIZE AND REGION (NO. OF COMPANIES)
  • TABLE 60 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • NORTH AMERICA
    • U.S.
    • TABLE 61 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS
    • TABLE 62 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
      • U.S. Market for Skin Tissue Engineering Products
      • TABLE 63 U.S. STATISTICS FOR SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011
    • U.S. MARKET FOR CARTILAGE AND BONE TISSUE ENGINEERING PRODUCTS
    • TABLE 64 U.S. STATISTICS FOR BONE DAMAGE AND RELATED DISEASES, 2010
    • U.S. MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISEASE
    • TABLE 65 U.S. STATISTICS FOR CARDIOVASCULAR DISEASE, 2014
    • CANADA
    • TABLE 66 TISSUE ENGINEERING RESEARCH CONDUCTED AS PER DIFFERENT UNIVERSITIES 137
    • TABLE 67 TISSUE ENGINEERING PRODUCTS OFFERED BY DIFFERENT COMPANIES 138
    • TABLE 68 CANADA STATISTICS FOR CARDIOVASCULAR DISEASE, 2014
    • TABLE 69 CANADA STATISTICS FOR SPINAL CORD INJURY, 2014
    • MEXICO
    • TABLE 70 MEXICO STATISTICS FOR CARDIOVASCULAR DISEASE, 2011-2014
    • TABLE 71 MEXICO STATISTICS FOR OTHER DISEASES AND INJURIES, 2012
    • EUROPE
    • TABLE 72 TISSUE ENGINEERING FIRMS, BY BUSINESS TYPE, 2014 (%)
    • TABLE 73 TISSUE ENGINEERING FIRMS IN FEW EUROPEAN COUNTRIES (%)
    • TABLE 74 EUROPEAN TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
    • GERMANY
    • TABLE 75 GERMANY STATISTICS FOR MORTALITY CAUSES, 2013
    • TABLE 76 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
    • U.K.
    • TABLE 77 DIFFERENT CAUSES OF DEATH: U.K. STATISTICS, 2013
    • TABLE 78 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
    • FRANCE
    • TABLE 79 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
    • OTHER EUROPEAN COUNTRIES
    • TABLE 80 STATISTICS FOR COST OF BONE DAMAGE REPAIR AND RELATED DISORDERS IN EUROPE
    • TABLE 81 CARDIOVASULAR DISEASE HEALTHCARE COST, BY COUNTRY, 2014 ($ BILLIONS)
    • TABLE 82 EUROPEAN STEM CELL POLICIES, BY COUNTRY
    • TABLE 83 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES
  • ASIA-PACIFIC
    • JAPAN
    • CHINA
    • AUSTRALIA
    • FIGURE 7 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE
    • TABLE 84 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • REST OF WORLD
  • TABLE 85 GLOBAL STATISTICS FOR SKIN-RELATED MEDICAL CONDITIONS, 2014
  • TABLE 86 REST OF WORLD TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
    • REST OF WORLD MARKET FOR CARTILAGE AND BONE TISSUE ENGINEERING PRODUCTS
    • REST OF WORLD MARKET FOR TISSUE ENGINEERING CARDIOVASCULAR DISEASE PRODUCTS
    • REST OF THE WORLD MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISEASES
    • TABLE 87 GLOBAL STATISTICS FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2015

CHAPTER 8 COMPETITIVE LANDSCAPE

  • FIGURE 8 KEY COMPETITIVE STRATEGIES, 2012-2016* (%)
  • APPROVAL
  • FIGURE 9 APPROVAL STRATEGY BY COMPANY*, 2012-2016 (%)
  • TABLE 88 KEY APPROVALS, 2012-2016
  • AGREEMENT, EXPANSION AND COLLABORATION
  • FIGURE 10 AGREEMENT, EXPANSION AND COLLABORATION STRATEGIES BY COMPANY*, 2012-2016
  • TABLE 89 KEY ANNOUNCED AGREEMENTS, EXPANSIONS AND COLLABORATIONS, 2012-2016
  • PRODUCT LAUNCHES AND PATENT APPROVALS
  • FIGURE 11 PRODUCT LAUNCH AND PATENT APPROVAL STRATEGIES BY COMPANY*, 2012-2016 (%)
  • TABLE 90 KEY ANNOUNCED PRODUCT LAUNCHES AND PATENT APPROVALS, 2012-2016
  • ACQUISTIONS AND MERGERS
  • FIGURE 12 ACQUISTIONS AND MERGERS STRATEGIES BY COMPANY*, 2012-2016
  • TABLE 91 KEY ANNOUNCED ACQUISTIONS AND MERGERS, 2012-2016

CHAPTER 9 PATENT ANALYSIS

  • FIGURE 13 GLOBALLY REGISTERED AND APPROVED PATENTS, 2016 (%)
  • FIGURE 14 U.S., EUROPE AND JAPAN REGISTERED AND APPROVED PATENTS, 2012-2016 (%)
  • FIGURE 15 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)
  • FIGURE 16 U.S. PATENT ANALYSIS BY APPLICATION, 2012-2016 (%)
  • FIGURE 17 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)
  • FIGURE 18 EUROPE PATENT ANALYSIS BY APPLICATION, 2011-2016 (%)
  • FIGURE 19 JAPAN PATENT ANALYSIS BY APPLICATION, 2011-2016 (%)
  • FIGURE 20 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)

CHAPTER 10 COMPANY PROFILES

  • ARTERIOCYTE MEDICAL SYSTEMS INC.
  • TABLE 92 ARTERIOCYTE MEDICAL SYSTEMS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • ATHERSYS INC.
  • TABLE 93 ATHERSYS INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 94 ATHERSYS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • CERAPEDICS INC.
  • TABLE 95 CERAPEDICS INC.: RECENT DEVELOPMENTS
    • TISSUE-ENGINEERING PRODUCT PORTFOLIO
  • CO.DON AG
  • TABLE 96 CO.DON AG: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • COOK MEDICAL INC.
  • TABLE 97 COOK MEDICAL INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • CRYOLIFE INC.
  • TABLE 98 CRYOLIFE INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 99 CRYOLIFE INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • CYTORI THERAPEUTICS INC.
  • TABLE 100 CYTORI THERAPEUTICS FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 101 CYTORI THERAPEUTICS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • GENZYME CORP.
  • TABLE 102 GENZYME CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 103 GENZYME: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • KINETIC CONCEPTS INC.
  • TABLE 104 KINETIC CONCEPTS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • MESOBLAST LTD.
  • TABLE 105 MESOBLAST LTD. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 106 MESOBLAST LTD.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • NUO THERAPEUTICS INC. (CYTOMEDIX INC.)
  • TABLE 107 NUO THERAPEUTICS INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 108 NUO THERAPEUTICS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • OCATA THERAPEUTICS INC. (ASTELLAS PHARMA INC.)
  • TABLE 109 ADVANCED CELL TECHNOLOGY INC.: RECENT DEVELOPMENTS
  • TISSUE-ENGINEERING PRODUCT PORTFOLIO
  • ORGANOGENESIS INC. (ADVANCED BIOHEALING)
  • TABLE 110 ORGANOGENESIS INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • ORTHOPEUTICS L.P.
  • TABLE 111 ORTHOPEUTICS: RECENT DEVELOPMENTS
  • U.S. STEM CELL INC. (BIOHEART INC.)
  • TABLE 112 U.S. STEM CELL INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 113 U.S. STEM CELL INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • VERICEL CORP. (AASTROM BIOSCIENCES INC.)
  • TABLE 114 VERICEL CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 115 VERICEL CORP.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • WRIGHT MEDICAL GROUP N.V
  • TABLE 116 WRIGHT MEDICAL GROUP N.V. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 117 WRIGHT MEDICAL TECHNOLOGY INC.: RECENT DEVELOPMENTS
    • TISSUE ENGINEERING PRODUCT PORTFOLIO

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 U.S. AND EUROPEAN DIFFERENCES IN REGULATORY APPROVAL
  • TABLE 2 MAIN ASPECTS OF HEALTHCARE PROVISIONS IN DIFFERENT COUNTRIES
  • TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING, BY COMPANY, 2010-2016
  • TABLE 4 COMPLETED U.S. CLINICAL TRIALS CONDUCTED FOR TISSUE ENGINEERING, 2004-2015
  • TABLE 5 TERMINATED U.S. CLINICAL TRIALS, 2012-2018
  • TABLE 6 EUROPEAN CLINICAL TRIALS CONDUCTED FOR TISSUE ENGINEERING, 2009-2019
  • TABLE 7 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 8 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY THERAPEUTIC PRODUCT, THROUGH 2021 ($ MILLIONS)
  • TABLE 9 GLOBAL CELL THERAPY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 10 PROJECTS AND THEIR ASSESSMENT STAGES (£) 55
  • TABLE 11 GLOBAL SMALL MOLECULES AND BIOLOGICS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 12 GLOBAL TISSUE ENGINEERING MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 13 GLOBAL GENE THERAPY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 14 GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY THERAPEUTIC MATERIAL, THROUGH 2021 ($ MILLIONS)
  • TABLE 15 GLOBAL SYNTHETIC MATERIAL MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 16 GLOBAL SYNTHETIC MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 17 BIODEGRADABLE POLYMER CLASSIFICATION 66
  • TABLE 18 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 19 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS 69
  • TABLE 20 GLOBAL SCAFFOLD MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 21 GLOBAL ARTIFICIAL VASCULAR GRAFT MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 22 GLOBAL HYDROGEL TECHNOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 23 GLOBAL BIOLOGICALLY DERIVED MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 GLOBAL BIOLOGICALLY DERIVED MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 25 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 27 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 30 GLOBAL GENETICALLY MANIPULATED CELL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 GLOBAL TRANSGENIC MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 GLOBAL FIBROBLAST MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 GLOBAL NEURAL STEM CELL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 GLOBAL GENE-ACTIVATED MATRIX MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 GLOBAL MARKET FOR SMALL MOLECULES AND BIOLOGICS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 37 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET, BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 39 CELL THERAPIES BY DIFFERENT COMPANIES TO TREAT CADIOVASULAR DISEASES
  • TABLE 40 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR ONCOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 41 GLOBAL AND U.S. STATISTICS FOR SKIN DAMAGE MEDICAL CONDITIONS, 2011
  • TABLE 42 ACELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 43 CELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 44 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR DERMATOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 45 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR MUSCULOSKELETAL APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 46 ORTHOPEDIC DISEASES BY REGION: KEY FACTS
  • TABLE 47 BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011 (NO. OF PEOPLE)
  • TABLE 48 GLOBAL STATISTICS FOR CARTILAGE DAMAGE, 2007
  • TABLE 49 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING
  • TABLE 50 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR WOUND HEALING APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 51 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR
  • OPHTHALMOLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 52 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET FOR NEUROLOGY APPLICATION, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 53 GLOBAL STATISTICS FOR NEURODEGENERATIVE DISEASES, 2015
  • TABLE 54 U.S. STATISTICS FOR SPINAL CORD INJURIES, 2015
  • TABLE 55 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 56 U.S. STATISTICS FOR LIVER FAILURE, 2011
  • TABLE 57 ARTIFICIAL LIVER SUPPORT SYSTEMS
  • TABLE 58 U.S. STATISTICS FOR PANCREATIC CANCER AND DIABETES, 2010
  • TABLE 59 U.S. STATISTICS FOR KIDNEY DISEASES, 2013
  • TABLE 60 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 61 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS
  • TABLE 62 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 63 U.S. STATISTICS FOR SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011
  • TABLE 64 U.S. STATISTICS FOR BONE DAMAGE AND RELATED DISEASES, 2010
  • TABLE 65 U.S. STATISTICS FOR CARDIOVASCULAR DISEASE, 2014
  • TABLE 66 TISSUE ENGINEERING RESEARCH CONDUCTED AS PER DIFFERENT UNIVERSITIES
  • TABLE 67 TISSUE ENGINEERING PRODUCTS OFFERED BY DIFFERENT COMPANIES
  • TABLE 68 CANADA STATISTICS FOR CARDIOVASCULAR DISEASE, 2014
  • TABLE 69 CANADA STATISTICS FOR SPINAL CORD INJURY, 2014
  • TABLE 70 MEXICO STATISTICS FOR CARDIOVASCULAR DISEASE, 2011-2014
  • TABLE 71 MEXICO STATISTICS FOR OTHER DISEASES AND INJURIES, 2012
  • TABLE 72 TISSUE ENGINEERING FIRMS, BY BUSINESS TYPE, 2014 (%)
  • TABLE 73 TISSUE ENGINEERING FIRMS IN FEW EUROPEAN COUNTRIES (%)
  • TABLE 74 EUROPEAN TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 75 GERMANY STATISTICS FOR MORTALITY CAUSES, 2013
  • TABLE 76 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
  • TABLE 77 DIFFERENT CAUSES OF DEATH: U.K. STATISTICS, 2013
  • TABLE 78 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
  • TABLE 79 COMPANIES THAT TARGET DIFFERENT TISSUE ENGINEERING AREAS
  • TABLE 80 STATISTICS FOR COST OF BONE DAMAGE REPAIR AND RELATED DISORDERS IN EUROPE
  • TABLE 81 CARDIOVASULAR DISEASE HEALTHCARE COST, BY COUNTRY, 2014 ($ BILLIONS)
  • TABLE 82 EUROPEAN STEM CELL POLICIES, BY COUNTRY
  • TABLE 83 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES
  • TABLE 84 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 85 GLOBAL STATISTICS FOR SKIN-RELATED MEDICAL CONDITIONS, 2014
  • TABLE 86 REST OF WORLD TISSUE ENGINEERING AND REGENERATION MARKET, BY COMPONENTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 87 GLOBAL STATISTICS FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2015
  • TABLE 88 KEY APPROVALS, 2012-2016
  • TABLE 89 KEY ANNOUNCED AGREEMENTS, EXPANSIONS AND COLLABORATIONS, 2012-2016
  • TABLE 90 KEY ANNOUNCED PRODUCT LAUNCHES AND PATENT APPROVALS, 2012-2016
  • TABLE 91 KEY ANNOUNCED ACQUISTIONS AND MERGERS, 2012-2016
  • TABLE 92 ARTERIOCYTE MEDICAL SYSTEMS INC.: RECENT DEVELOPMENTS
  • TABLE 93 ATHERSYS INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 94 ATHERSYS INC.: RECENT DEVELOPMENTS
  • TABLE 95 CERAPEDICS INC.: RECENT DEVELOPMENTS
  • TABLE 96 CO.DON AG: RECENT DEVELOPMENTS
  • TABLE 97 COOK MEDICAL INC.: RECENT DEVELOPMENTS
  • TABLE 98 CRYOLIFE INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 99 CRYOLIFE INC.: RECENT DEVELOPMENTS
  • TABLE 100 CYTORI THERAPEUTICS FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 101 CYTORI THERAPEUTICS INC.: RECENT DEVELOPMENTS
  • TABLE 102 GENZYME CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 103 GENZYME: RECENT DEVELOPMENTS
  • TABLE 104 KINETIC CONCEPTS INC.: RECENT DEVELOPMENTS
  • TABLE 105 MESOBLAST LTD. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 106 MESOBLAST LTD.: RECENT DEVELOPMENTS
  • TABLE 107 NUO THERAPEUTICS INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 108 NUO THERAPEUTICS INC.: RECENT DEVELOPMENTS
  • TABLE 109 ADVANCED CELL TECHNOLOGY INC.: RECENT DEVELOPMENTS
  • TABLE 110 ORGANOGENESIS INC.: RECENT DEVELOPMENTS
  • TABLE 111 ORTHOPEUTICS: RECENT DEVELOPMENTS
  • TABLE 112 U.S. STEM CELL INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 113 U.S. STEM CELL INC.: RECENT DEVELOPMENTS
  • TABLE 114 VERICEL CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 115 VERICEL CORP.: RECENT DEVELOPMENTS
  • TABLE 116 WRIGHT MEDICAL GROUP N.V. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TABLE 117 WRIGHT MEDICAL TECHNOLOGY INC.: RECENT DEVELOPMENTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION, BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 1 TISSUE ENGINEERING STRATEGIES
  • FIGURE 2 NANOTECHNOLOGY AND TISSUE REGENERATION
  • FIGURE 3 PORTER'S FIVE FORCES MODEL FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE MARKET
  • FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2011-2016 (NO. OF STUDIES)
  • FIGURE 5 T-CELL THERAPY TECHNIQUE
  • FIGURE 6 REGENERATIVE MEDICINE COMPANIES BY SIZE AND REGION (NO. OF COMPANIES)
  • FIGURE 7 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE
  • FIGURE 8 KEY COMPETITIVE STRATEGIES, 2012-2016* (%)
  • FIGURE 9 APPROVAL STRATEGY BY COMPANY*, 2012-2016 (%)
  • FIGURE 10 AGREEMENT, EXPANSION AND COLLABORATION STRATEGIES BY COMPANY*, 2012-2016
  • FIGURE 11 PRODUCT LAUNCH AND PATENT APPROVAL STRATEGIES BY COMPANY*, 2012-2016 (%)
  • FIGURE 12 ACQUISTIONS AND MERGERS STRATEGIES BY COMPANY*, 2012-2016
  • FIGURE 13 GLOBALLY REGISTERED AND APPROVED PATENTS, 2016 (%)
  • FIGURE 14 U.S., EUROPE AND JAPAN REGISTERED AND APPROVED PATENTS, 2012-2016 (%)
  • FIGURE 15 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)
  • FIGURE 16 U.S. PATENT ANALYSIS BY APPLICATION, 2012-2016 (%)
  • FIGURE 17 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)
  • FIGURE 18 EUROPE PATENT ANALYSIS BY APPLICATION, 2011-2016 (%)
  • FIGURE 19 JAPAN PATENT ANALYSIS BY APPLICATION, 2011-2016 (%)
  • FIGURE 20 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2016 (%)
Back to Top